[ad_1] Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For Xipere on @EyeWireNews https://t.co/CefpnRcEbg [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @MDPIpharma: #MDPIPharmaceutics š Suprachoroidal targeting of chorioretina in 4 trials: CLS-AX – AMD, RGXā314 – AMD/DR & AUā011 – choroiā¦ [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @RetinalPhys: The Latest on Drug Delivery in the Suprachoroidal Space: Maximize treatment effect and minimize exposure to other ocular tā¦
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Congrats to our colleagues & team, who had numerous presentations at this year’s ARVO on suprachoroidal space delivery platform, gene therapy, CLS-TA, & treatment burden and unmet needs with current anti-VEGF-A therapies… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] Retinal OCT for Clinicians https://t.co/rwa3BS3Lew via @YouTube [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @RetinalPhys: Our most read article from the April issue is “Retinal OCT Biomarkers for Clinicians and Clinical Researchers.” @ThomasCiuā¦
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @RetinalPhys: Retinal OCT Biomarkers for Clinicians and Clinical Researchers: Recent studies may yield meaningful prognostic and treatmeā¦ [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] OIS Podcast Episode #270: KOLs Speak Out on the Future of Gene Therapy https://t.co/nXMnR91Btg via @YouTube [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
Gene Therapy for Retinal Disease https://t.co/CDezBt3HxD via @YouTube
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Given recent clinical trial results in geographic atrophy/dry AMD, there has been great interest in our review of complement inhibition as a therapeutic strategy in retinal disorders #retina #eye #macula #AMD #clinicaltrials https://t.co/z4YaBgcE1n [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.